Cryoablation
Phase 3Small molecule
Cryoablation is one of 67 small molecule programs targeting Metastasis. It is currently in Phase 3.
2
Indications
4
Total Trials
2
Active Trials
66
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
64 competitors in Metastasis
#DrugCompanyPhaseTrials
1Femara
NovartisApproved
Taxol
TevaApproved
Camptosar
PfizerApproved
Gemzar
Johnson & JohnsonApproved
Trexall
Jazz PharmaceuticalsApproved
Norvir
AbbVieApproved
Neoral
NovartisApproved
Lynparza
AstraZenecaApproved
Tukysa
PfizerApproved
Keytruda
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastasis2 trials
Intrahepatic Cholangiocarcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cryoablation. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- FFudan University